The estimated Net Worth of Wayde D. Mc Millan is at least 11.4 百万$ dollars as of 3 July 2023. Mr. Millan owns over 1,388 units of Insulet stock worth over 4,890,957$ and over the last 6 years he sold PODD stock worth over 2,081,414$. In addition, he makes 4,474,090$ as Chief Financial Officer、 Executive Vice President、 Treasurer at Insulet.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. McMillan PODD stock SEC Form 4 insiders trading
Wayde has made over 5 trades of the Insulet stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,388 units of PODD stock worth 392,721$ on 3 July 2023.
The largest trade he's ever made was selling 1,855 units of Insulet stock on 31 December 2021 worth over 498,958$. On average, Wayde trades about 366 units every 27 days since 2019. As of 3 July 2023 he still owns at least 21,477 units of Insulet stock.
You can see the complete history of Mr. Millan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wayde McMillan biography
Wayde D. McMillan serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. Mr. McMillan has served as our Executive Vice President, Chief Financial Officer and Treasurer since March 2019. From January 2015 to March 2019, he was Chief Financial Officer and Vice President of Finance of the Minimally Invasive Therapies Group at Medtronic plc. From November 2006 to January 2015, prior to Medtronic’s acquisition of Covidien plc, Mr. McMillan held a variety of leadership positions at Covidien, including Chief Financial Officer and Vice President of Finance of the Medical Devices Group & U.S., Chief Financial Officer and Vice President of Finance of the Surgical Solutions Business Unit, and Vice President Finance and Controller of the Respiratory and Monitoring Solutions Business Unit. Mr. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions. Mr. McMillan earned his Bachelor of Science in Business Administration from Merrimack College and a Master of Business Administration from the Bentley University McCallum Graduate School of Business.
What is the salary of Wayde McMillan?
As the Chief Financial Officer、 Executive Vice President、 Treasurer of Insulet, the total compensation of Wayde McMillan at Insulet is 4,474,090$. There are 1 executives at Insulet getting paid more, with Shacey Petrovic having the highest compensation of 5,883,980$.
How old is Wayde McMillan?
Wayde McMillan is 50, he's been the Chief Financial Officer、 Executive Vice President、 Treasurer of Insulet since 2019. There are 16 older and 5 younger executives at Insulet. The oldest executive at Insulet Corporation is John Fallon, 72, who is the Independent Director.
What's Wayde McMillan's mailing address?
Wayde's mailing address filed with the SEC is C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON, MA, 01720.
Insiders trading at Insulet
Over the last 18 years, insiders at Insulet have traded over 64,849,299$ worth of Insulet stock and bought 175,262 units worth 7,280,516$ . The most active insiders traders include Jonathan Silverstein、Elizabeth H Weatherman、Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of 2,473,148$. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth 1,129,200$.
What does Insulet do?
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
What does Insulet's logo look like?
Complete history of Mr. Millan stock trades at Insulet
Insulet executives and stock owners
Insulet executives and other stock owners filed with the SEC include:
-
Shacey Petrovic,
President, Chief Executive Officer, Director -
Wayde McMillan,
Chief Financial Officer, Executive Vice President, Treasurer -
Charles Alpuche,
Chief Operating Officer, Executive Vice President -
Bret Christensen,
Executive Vice President and Chief Commercial Officer -
John Kapples,
Senior Vice President, General Counsel, Secretary -
Shacey Petrovic,
Pres, CEO & Director -
Michael Spears,
Senior Vice President - Regulatory Affairs and Compliance -
Charles Alpuche,
Exec. VP & COO -
Wayde D. McMillan,
Exec. VP,CFO & Treasurer -
Bret Christensen,
Exec. VP & Chief Commercial Officer -
Dan Manea,
Sr. VP & Chief HR Officer -
Corinne Nevinny,
Independent Director -
timothy Scannell,
Independent Chairman of the Board -
James Hollingshead,
Independent Director -
David Lemoine,
Independent Director -
Sally Crawford,
Independent Director -
Jessica Hopfield,
Independent Director -
Michael Minogue,
Independent Director -
John Fallon,
Independent Director -
Deborah Gordon,
Vice President - Investor Relations and Corporate Communications -
Wayne Frederick,
Director -
Eric Benjamin,
Senior Vice President, Innovation and Strategy -
John Wodick Kapples,
Sr. VP, Sec. & Gen. Counsel -
Michael Spears,
Sr. VP of Regulatory Affairs & Compliance -
Angela Geryak Wiczek,
Sr. Director of Corp. Communications -
Lauren Budden,
VP, Chief Accounting Officer & Controller -
David Colleran,
SVP, Secretary and GC -
Regina O Sommer,
Director -
Michael L Levitz,
CFO -
Bradley A Thomas,
EVP Human Resources -
Joseph S Zakrzewski,
Director -
Daniel J Levangie,
Director -
Luciana Borio,
Director -
James C Mullen,
Director -
John Garibotto,
Vice President of Research -
Luis Malave,
Chief Operating Officer -
Aiman Abdel Malek,
SVP, Advanced Technology -
Ruthann De Pietro,
Vice President of Quality -
Patrick J Sullivan,
President & CEO -
Ross A Md Jaffe,
Director -
Carsten Boess,
Chief Financial Officer -
David A Howe,
VP of Human Resources -
Jason Ng,
Vice President of Asian Operat -
W Mark Lortz,
Director -
Steven Sobieski,
Director -
William D Iii Arthur,
V.P. of Business Development -
Peter Devlin,
Chief Commercial Officer -
Brian K Roberts,
Chief Financial Officer -
Lars Boesgaard,
Vice President of Finance -
Shawna Gvazdauskas,
Vice President of Sales -
R Anthony Diehl,
General Counsel -
Gary Eichhorn,
Director -
Kevin Schmid,
Vice President Manufacturing -
John L Brooks,
10% owner -
Charles T Liamos,
Director -
Allison Dorval,
Chief Financial Officer -
Tracey Haas Wielinski,
VP, Global Regulatory, CA, QA -
William Patrick Ryan,
Chief Operating Officer -
Duane De Sisto,
President and CEO -
Advisors Llc Orbimed,
Director -
Andrew Suchoff,
Chief Human Resources Officer -
Venture Capital I Lpversant...,
-
Venture Partners Iii Llc Prism,
10% owner -
Jonathan Silverstein,
Director -
Venture Partners Iii A Lp P...,
10% owner -
Venture Partners Iii Lp Prism,
10% owner -
Venture Partners Iii A Lp P...,
-
De Bord Alison Peyromaure,
Director -
Capital Management Inc Pequot,
-
Investment Partners Iii Lp ...,
10% owner -
Stephen Bubrick,
Vice President of Customer -
William M Seifert,
10% owner -
Gordon E Nye,
10% owner -
Samuel D Colella,
-
Jefferey Smith,
Vice President of Marketing -
Robert Campbell,
Vice President for Clinical -
Dan Manea,
SVP, Chief HR Officer -
Prem Singh,
SVP, Global Operations -
Timothy C. Stonesifer,
Director -
Flavia Pease,
Director -
Elizabeth H Weatherman,
Director -
Lauren Budden,
Group VP, CAO and Controller -
Laetitia Cousin,
SVP, Reg, Quality & Compliance -
Mark N Field,
SVP & Chief Technology Officer -
Ana Maria Chadwick,
EVP, CFO & Treasurer